The latest price target for Lyra Therapeutics (NASDAQ:LYRA) was reported by Cantor Fitzgerald on August 15, 2024. The analyst firm set a price target for $0.00 expecting LYRA to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Lyra Therapeutics (NASDAQ:LYRA) was provided by Cantor Fitzgerald, and Lyra Therapeutics reiterated their overweight rating.

There is no last upgrade for Lyra Therapeutics

The last downgrade for Lyra Therapeutics Inc happened on May 7, 2024 when HC Wainwright & Co. changed their price target from N/A to $2 for Lyra Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyra Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyra Therapeutics was filed on August 15, 2024 so you should expect the next rating to be made available sometime around August 15, 2025.

While ratings are subjective and will change, the latest Lyra Therapeutics (LYRA) rating was a reiterated with a price target of $0.00 to $0.00. The current price Lyra Therapeutics (LYRA) is trading at is $0.27, which is out of the analyst’s predicted range.